<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550795</url>
  </required_header>
  <id_info>
    <org_study_id>Breast PONV</org_study_id>
    <secondary_id>GCIRB2014</secondary_id>
    <nct_id>NCT02550795</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer</brief_title>
  <official_title>Effects of Single Dose Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports demonstrated that dexmedetomidine could reduce the incidence of&#xD;
      postoperative nausea and vomiting (PONV). Dexamethason also had been commonly used for&#xD;
      ajuvant drugs for preventing and reducing PONV. So investigator want to study about the&#xD;
      effect of dexmedetomidine only or combined with dexamethasone for preventing PONV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous reports demonstrated that dexmedetomidine, a alpha 2 selective agonist could reduce&#xD;
      the incidence of postoperative nausea and vomiting (PONV). Dexamethason also had been&#xD;
      commonly used for ajuvant drugs for preventing and reducing PONV. So investigator want to&#xD;
      study about the effect of dexmedetomidine only or combined with dexamethasone for preventing&#xD;
      PONV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Nausea (Numeric Rating Scale for Nausea)</measure>
    <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
    <description>Numeric rating scale for postoperative nausea (scores on a scale) (0-no symptoms; 10-worst symptoms imaginable). Ramosetron 0.3 mg was administered to patients with nausea &gt;5 points on the numeric rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Vomiting (Number of Participants With Vomiting)</measure>
    <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
    <description>frequencies of vomiting (number of participants with vomiting) 24 hour post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhodes Index Score</measure>
    <time_frame>assessed at 6 and 24 hour after operative end</time_frame>
    <description>Rhodes Index of nausea, vomiting, and retching at 6 to 24 hours after surgery (ask 8 question about discomfort due to PONV and each questions are consist of 0~4 score) (minimal PONV 0 to maximal PONV 32) lower values represent a bettwer outcome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of 0.9% normal saline 10ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 0.5ug/kg of dexmedetomidine (5ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>administration of dexmedetomidine only</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>DO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine and dexamethasone</intervention_name>
    <description>administration of dexmedetomidine and dexamethasone</description>
    <arm_group_label>Dexmedetomidine and dexamethasone</arm_group_label>
    <other_name>DD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>administration of normal saline</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>OO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA Physical status I or II female scheduled for breast conserving surgery of modified&#xD;
             radical mastectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled cardiovascular disease&#xD;
&#xD;
          -  history of chronic pain&#xD;
&#xD;
          -  smoker&#xD;
&#xD;
          -  previous history of steroid administraion&#xD;
&#xD;
          -  neoajuvant chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <results_first_submitted>February 14, 2019</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Youn Yi Jo</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was no one who excluded before assignment to groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine</title>
          <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
        </group>
        <group group_id="P3">
          <title>Dexmedetomidine and Dexamethasone</title>
          <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine</title>
          <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
        </group>
        <group group_id="B3">
          <title>Dexmedetomidine and Dexamethasone</title>
          <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>one patient excluded from the analysis according to changes of surgery method</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="6.4"/>
                    <measurement group_id="B2" value="48.2" spread="7.1"/>
                    <measurement group_id="B3" value="48.4" spread="7.5"/>
                    <measurement group_id="B4" value="48.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Nausea (Numeric Rating Scale for Nausea)</title>
        <description>Numeric rating scale for postoperative nausea (scores on a scale) (0-no symptoms; 10-worst symptoms imaginable). Ramosetron 0.3 mg was administered to patients with nausea &gt;5 points on the numeric rating scale</description>
        <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
        <population>Patients who underwent breast cancer surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine and Dexamethasone</title>
            <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea (Numeric Rating Scale for Nausea)</title>
          <description>Numeric rating scale for postoperative nausea (scores on a scale) (0-no symptoms; 10-worst symptoms imaginable). Ramosetron 0.3 mg was administered to patients with nausea &gt;5 points on the numeric rating scale</description>
          <population>Patients who underwent breast cancer surgery</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Vomiting (Number of Participants With Vomiting)</title>
        <description>frequencies of vomiting (number of participants with vomiting) 24 hour post-operatively</description>
        <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
        <population>Patients who underwent breast cancer surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine and Dexamethasone</title>
            <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Vomiting (Number of Participants With Vomiting)</title>
          <description>frequencies of vomiting (number of participants with vomiting) 24 hour post-operatively</description>
          <population>Patients who underwent breast cancer surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-6 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-24hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhodes Index Score</title>
        <description>Rhodes Index of nausea, vomiting, and retching at 6 to 24 hours after surgery (ask 8 question about discomfort due to PONV and each questions are consist of 0~4 score) (minimal PONV 0 to maximal PONV 32) lower values represent a bettwer outcome</description>
        <time_frame>assessed at 6 and 24 hour after operative end</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine and Dexamethasone</title>
            <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Rhodes Index Score</title>
          <description>Rhodes Index of nausea, vomiting, and retching at 6 to 24 hours after surgery (ask 8 question about discomfort due to PONV and each questions are consist of 0~4 score) (minimal PONV 0 to maximal PONV 32) lower values represent a bettwer outcome</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-6 hour after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-24 hour after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="13"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>administration of 0.9% normal saline 10ml&#xD;
Control: administration of normal saline</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine</title>
          <description>administration of 0.5ug/kg of dexmedetomidine (5ml)&#xD;
Dexmedetomidine: administration of dexmedetomidine only</description>
        </group>
        <group group_id="E3">
          <title>Dexmedetomidine and Dexamethasone</title>
          <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)&#xD;
Dexmedetomidine and dexamethasone: administration of dexmedetomidine and dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Youn Yi Jo</name_or_title>
      <organization>Gil hospital</organization>
      <phone>82324603636</phone>
      <email>endless37@gilhospital.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

